Kodiak Sciences reports Q4 EPS 84c, consensus (86c)

Ended Q4 with $168.1M of cash and cash equivalents and believes current cash will support current and planned operations into 2026. “In September of 2024 we hosted an Investor R&D Day in New York,” said CEO Victor Perlroth. “It is remarkable that after twenty years of anti-VEGF therapy, retinal commercial franchises continue to be a major driver of revenue and profitability within large pharma companies. This sustained commercial success is a testament to the power of the intravitreal biologic as the mainstay of therapy and also a testament to the unmet need that remains for patients. We have two strong contenders in the anti-VEGF category, tarcocimab and KSI-501. Both are built with our ABC platform, where our enhanced formulation is intended to bring a strong pulse of anti-VEGF to power immediacy of effect and our antibody conjugate is designed to bring a true science of durability to power long-interval dosing.”